Amarin reported $25.13M in Gross Profit on Sales for its fiscal quarter ending in March of 2025.


Gross Profit On Sales Change Date
AbbVie USD 9.34B 1.36B Mar/2025
Alnylam Pharmaceuticals USD 630.74M 107.59M Jun/2025
Amarin USD 25.13M 1.78M Mar/2025
AstraZeneca USD 11.98B 637M Jun/2025
DBV Technologies -30442000 30.56M Sep/2024
GlaxoSmithKline GBP 5.82B 229M Jun/2025
Halozyme Therapeutics USD 279.36M 62.9M Jun/2025
Ionis Pharmaceuticals USD 448M 317.85M Jun/2025
Neurocrine Biosciences USD 676.2M 112.8M Jun/2025
Novartis USD 11.51B 1.12B Jun/2025